140 related articles for article (PubMed ID: 36173339)
1. Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.
He H; Zhang Y; Xu J; Li Y; Fang H; Liu Y; Zhang S
J Med Chem; 2022 Oct; 65(19):13158-13171. PubMed ID: 36173339
[TBL] [Abstract][Full Text] [Related]
2. Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma.
Zhang S; Zhang Y; Chen X; Xu J; Fang H; Li Y; Liu Y; He H
J Med Chem; 2022 Dec; 65(23):15856-15877. PubMed ID: 36384290
[TBL] [Abstract][Full Text] [Related]
3. Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.
He H; Chen R; Wang Z; Qing L; Zhang Y; Liu Y; Pan W; Fang H; Zhang S
Bioorg Chem; 2023 Jul; 136():106536. PubMed ID: 37054529
[TBL] [Abstract][Full Text] [Related]
4. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
Ketcham JM; Haling J; Khare S; Bowcut V; Briere DM; Burns AC; Gunn RJ; Ivetac A; Kuehler J; Kulyk S; Laguer J; Lawson JD; Moya K; Nguyen N; Rahbaek L; Saechao B; Smith CR; Sudhakar N; Thomas NC; Vegar L; Vanderpool D; Wang X; Yan L; Olson P; Christensen JG; Marx MA
J Med Chem; 2022 Jul; 65(14):9678-9690. PubMed ID: 35833726
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.
Chen T; Tang X; Wang Z; Feng F; Xu C; Zhao Q; Wu Y; Sun H; Chen Y
Eur J Med Chem; 2023 Dec; 261():115828. PubMed ID: 37778239
[TBL] [Abstract][Full Text] [Related]
6. Targeting Son of Sevenless 1: The pacemaker of KRAS.
Kessler D; Gerlach D; Kraut N; McConnell DB
Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
[TBL] [Abstract][Full Text] [Related]
7. One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
Ramharter J; Kessler D; Ettmayer P; Hofmann MH; Gerstberger T; Gmachl M; Wunberg T; Kofink C; Sanderson M; Arnhof H; Bader G; Rumpel K; Zöphel A; Schnitzer R; Böttcher J; O'Connell JC; Mendes RL; Richard D; Pototschnig N; Weiner I; Hela W; Hauer K; Haering D; Lamarre L; Wolkerstorfer B; Salamon C; Werni P; Munico-Martinez S; Meyer R; Kennedy MD; Kraut N; McConnell DB
J Med Chem; 2021 May; 64(10):6569-6580. PubMed ID: 33719426
[TBL] [Abstract][Full Text] [Related]
8. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Hofmann MH; Gmachl M; Ramharter J; Savarese F; Gerlach D; Marszalek JR; Sanderson MP; Kessler D; Trapani F; Arnhof H; Rumpel K; Botesteanu DA; Ettmayer P; Gerstberger T; Kofink C; Wunberg T; Zoephel A; Fu SC; Teh JL; Böttcher J; Pototschnig N; Schachinger F; Schipany K; Lieb S; Vellano CP; O'Connell JC; Mendes RL; Moll J; Petronczki M; Heffernan TP; Pearson M; McConnell DB; Kraut N
Cancer Discov; 2021 Jan; 11(1):142-157. PubMed ID: 32816843
[No Abstract] [Full Text] [Related]
9. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.
Leshchiner ES; Parkhitko A; Bird GH; Luccarelli J; Bellairs JA; Escudero S; Opoku-Nsiah K; Godes M; Perrimon N; Walensky LD
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1761-6. PubMed ID: 25624485
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
[TBL] [Abstract][Full Text] [Related]
12. Discovery of LHF418 as a new potent SOS1 PROTAC degrader.
Li H; Chai M; Chen Y; Zhou F; Ren X; Xu J; Wang J; Wang Z; Huang W
Bioorg Med Chem; 2024 Apr; 103():117661. PubMed ID: 38489998
[TBL] [Abstract][Full Text] [Related]
13. Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.
Begovich K; Schoolmeesters A; Rajapakse N; Martinez-Terroba E; Kumar M; Shakya A; Lai C; Greene S; Whitefield B; Okano A; Mali V; Huang S; Chourasia AH; Fung L
Mol Cancer Ther; 2024 Apr; 23(4):407-420. PubMed ID: 38224565
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo.
Pang X; Cui D; Lv B; Wang CY
J Med Chem; 2024 Jan; 67(2):1563-1579. PubMed ID: 38206836
[TBL] [Abstract][Full Text] [Related]
15. Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras.
Hamilton G; Stickler S; Rath B
Curr Pharm Des; 2023; 29(22):1741-1746. PubMed ID: 37073657
[TBL] [Abstract][Full Text] [Related]
16. Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.
Xiao Z; Li L; Li Y; Zhou W; Cheng J; Liu F; Zheng P; Zhang Y; Che Y
Cell Death Dis; 2014 May; 5(5):e1241. PubMed ID: 24853419
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
Smith CR; Chen D; Christensen JG; Coulombe R; Féthière J; Gunn RJ; Hollander J; Jones B; Ketcham JM; Khare S; Kuehler J; Lawson JD; Marx MA; Olson P; Pearson KE; Ren C; Tsagris D; Ulaganathan T; Van't Veer I; Wang X; Ivetac A
J Med Chem; 2024 Jan; 67(1):774-781. PubMed ID: 38156904
[TBL] [Abstract][Full Text] [Related]
18. Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature.
Thompson SK; Buckl A; Dossetter AG; Griffen E; Gill A
Expert Opin Ther Pat; 2021 Dec; 31(12):1189-1204. PubMed ID: 34253125
[No Abstract] [Full Text] [Related]
19. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of quinazoline SOS1 inhibitors.
Jiang H; Fan Y; Wang X; Wang J; Yang H; Fan W; Tang C
Bioorg Med Chem Lett; 2023 May; 88():129265. PubMed ID: 37011767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
